CDISC’s Requirements About SEND

SEND (Standard for Exchange of Nonclinical Data, Non-Clinical Data Interchange Standards Consortium）Clinical Data Interchange Standards Consortium (Clinical Data Interchange Standards Consortium) Numerical formalism.

On September 15th of this year, the FDA CDER issued an enforcement request IND and an NDA/BLA application, supporting the submission of a non-payment test SEND number (Dataset). The Dataset code for the data set is to be confirmed and sent by the FDA SEND formal communication request.

Mr. Harahara, Director of FDA standardization research. Origin: FDA

When did it Start to Operate the SEND Dataset?

FDA CDER general request IND on September 15, 2021, support NDA/BLA China-China demand negotiations, non-table trial SEND Dataset, including comprehensive GLP and non-GLP trial. If the SEND Dataset cannot be passed, the FDA approval has been rejected.

SENDIG is a reference-specific SDTM model. However, SDTM is a comprehensive model of the original capital. In this case, this small model is compatible with both directions. SENDIG supports multiple-dose general toxicology, multiple-dose general toxicology, carcinogenicity research, and safety science research.

Support for other research categories than SENDIG. For example, SENDIG-DART v1.2 has been established, and DART research collection includes certain specific numerical recommendations, especially embryo-fetal development (EFD) research, and juvenile animal behavioral toxicity research. SENDIG-AR v1.0 Supports the basic infrastructure and ongoing research. In addition to the model implementation guidelines, we will develop the consistency guideline, so you can be sure of the generative number structure combination.

Under what circumstances will FDA refuse to accept a submitted SEND Dataset?

If the submitted SEND Dataset has the following problems, FDA will refuse to accept it:

• Missing corresponding ts.xpt Dataset

• Incorrectly filling in the STF file tag of Dataset

• Missing DM Dataset and define.xml

• Missing STF files

Reference:

[1]. CDISC Website: SEND. https://www.cdisc.org/standards/foundational/send

此博客中的热门博文

What is preclinical testing?

In the process of preclinical testing of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a preclinical research phase followed, before which, as described above, the potential toxicity of the compou

阅读全文

Inventory of the three major in vitro pharmacokinetic research methods

The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d

阅读全文

Novel Parkinson’s Therapies Possible with New Mouse Model

Parkinson's disease (PD) is a neurodegenerative disorder that is marked by the accumulation of the protein, α-synuclein (αS), into clumps known as Lewy bodies, which diminish neural health. Now, researchers from Brigham and Women's Hospital (BWH) report the development of a mouse model to induce PD-like αS aggregation, leading to resting tremor and abnormal movement control. The mouse responds to L-DOPA, similarly to patients with PD. The team's study (“Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson’s Disease”) on the use of this transgenic mouse model appears in Neuron . “α-Synuclein (αS) regulates vesicle exocytosis but forms insoluble deposits in PD. Developing disease-modifying therapies requires animal models that reproduce cardinal features of PD. We recently described a previously unrecognized physiological form of αS, α-helical tetramers, and showed that familial PD-causing missense mutati

阅读全文

Shanghai Medicilon Inc.

搜索此博客